Search Results

You are looking at 61 - 70 of 832 items for :

  • Refine by Access: All x
Clear All
Full access

Multiple Myeloma, Version 1.2013

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr, Cristina Gasparetto, Francisco Hernandez-Illizaliturri, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Michael Liedtke, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Furhan Yunus, Dorothy A. Shead, and Rashmi Kumar

responsible for MM has led to the development of novel agents. The availability of many novel evidence-based options for the treatment of MM has led to significant improvements in response and survival. Most patients with MM experience relapse or become

Full access

Updates in the Treatment of Multiple Myeloma

Presented by: Shaji K. Kumar

diagnosis for patients with active myeloma that needs treatment, and to incorporate risk stratification, which is critical in terms of deciding upon the overall treatment goals and approaches over time . . . . Unfortunately, patients continue to relapse. We

Full access

In Defense of Hepatic Arterial Infusion for Hepatic Metastases of Colorectal Cancer

Nancy Kemeny

infusion. Results were compared with those of 125 consecutive patients who received adjuvant folfox or folfiri after resection with a median follow-up of 43 months. Abbreviations: FUDR, floxuridine; HAI, hepatic arterial infusion; RFS, relapse

Full access

Optimization of Postremission Therapy in Follicular Lymphoma: Efficacy of Rituximab Maintenance

Rupali Roy and Leo I. Gordon

repeated relapses. The standard management for patients who have asymptomatic follicular lymphoma is to “watch and wait.” In the pre-rituximab era, multiple randomized phase III trials compared immediate treatment with chemotherapy and observation for

Full access

Multiple Myeloma: Advances Reported in 2013 Are Useful in the Clinic

Kenneth Anderson

the results are very impressive, indeed,” Dr. Anderson noted. “This is exciting because it is an all-oral regimen without much neuropathy.” Relapsed/Refractory Disease “We have very exciting initial therapy, we have consolidation treatments

Full access

Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma

Paul D. Harker-Murray, Lauren Pommert, and Matthew J. Barth

neutropenia, and infections, compared with other pediatric B-NHL chemotherapy backbones, 17 , 23 and has been adopted as the standard therapy for this group of patients. Relapsed B-NHL Relapsed pediatric B-NHL has a very poor prognosis with survival rates

Full access

Chronic Lymphocytic Leukemia: Individualizing Treatment Approach

Andrew D. Zelenetz

“Chronic lymphocytic leukemia [CLL] is a continuum of disease. Although a number of patients will never be treated for their disease (indolent CLL; “early” asymptomatic), most patients will move on to active CLL (“later” symptomatic) or relapsed

Full access

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Patrick Brown, Hiroto Inaba, Colleen Annesley, Jill Beck, Susan Colace, Mari Dallas, Kenneth DeSantes, Kara Kelly, Carrie Kitko, Norman Lacayo, Nicole Larrier, Luke Maese, Kris Mahadeo, Ronica Nanda, Valentina Nardi, Vilmarie Rodriguez, Jenna Rossoff, Laura Schuettpelz, Lewis Silverman, Jessica Sun, Weili Sun, David Teachey, Victor Wong, Gregory Yanik, Alyse Johnson-Chilla, and Ndiya Ogba

management of ALL. This portion of the NCCN Guidelines discusses recommendations for the diagnosis and workup of pediatric ALL and focuses on frontline and relapsed/refractory (R/R) management strategies for B-ALL, T-ALL, and infants with ALL. For the

Full access

Acute Lymphoblastic Leukemia, Version 2.2015

Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Stefan K. Barta, Uma Borate, Michael W. Boyer, Patrick W. Burke, Ryan Cassaday, Januario E. Castro, Peter F. Coccia, Steven E. Coutre, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Olga Frankfurt, John P. Greer, Robert A. Johnson, Hagop M. Kantarjian, Rebecca B. Klisovic, Gary Kupfer, Mark Litzow, Arthur Liu, Arati V. Rao, Bijal Shah, Geoffrey L. Uy, Eunice S. Wang, Andrew D. Zelenetz, Kristina Gregory, and Courtney Smith

, the treatment of relapsed/refractory ALL, and the role of minimal residual disease (MRD) evaluation. Please refer to NCCN.org for the complete guidelines. ALL is a heterogeneous hematologic disease characterized by the proliferation of immature

Full access

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017

Patrick A. Brown, Bijal Shah, Amir Fathi, Matthew Wieduwilt, Anjali Advani, Patricia Aoun, Stefan K. Barta, Michael W. Boyer, Teresa Bryan, Patrick W. Burke, Ryan Cassaday, Peter F. Coccia, Steven E. Coutre, Lloyd E. Damon, Daniel J. DeAngelo, Olga Frankfurt, John P. Greer, Hagop M. Kantarjian, Rebecca B. Klisovic, Gary Kupfer, Mark Litzow, Arthur Liu, Ryan Mattison, Jae Park, Jeffrey Rubnitz, Ayman Saad, Geoffrey L. Uy, Eunice S. Wang, Kristina M. Gregory, and Ndiya Ogba

pathogenesis of ALL, the incorporation of risk-adapted therapy, the advent of new targeted agents, and the use of allogeneic hematopoietic cell transplantation (HCT). However, the treatment of patients who experience relapse after initial therapy remains a